Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort

Clinica Chimica Acta

Volumn 416, Issue , 2013, Pages 41-47

  Burri, Emanuel ^a,b   Manz, Michael ^a   Rothen, Claude ^c   Rossi, Livio ^a   Beglinger, Christoph ^a   Lehmann, Frank Serge ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

^c Rothen Medical Laboratories   (Switzerland)

Author keywords

ELISA; Fecal calprotectin; Fecal lactoferrin; Monoclonal; Sensitivity

Indexed keywords

CALGRANULIN; LACTOFERRIN; MONOCLONAL ANTIBODY;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENDOSCOPY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; INTESTINAL DISEASES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; PROSPECTIVE STUDIES; ROC CURVE; SWITZERLAND;

EID: 84871458275     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.11.008     Document Type: Article

References (29)

1. Gisbert J.P., McNicholl A.G. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009, 41:56-66.
2. Gisbert J.P., McNicholl A.G., Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1746-1754.
3. Tibble J., Sigthorsson G., Foster R., Sherwood R., Fagerhol M., Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001, 49:402-408.
4. Kristinsson J., Armbruster C.H., Ugstad M., et al. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 2001, 36:202-207.
5. Wildt S., Nordgaard-Lassen I., Bendtsen F., Rumessen J.J. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007, 19:567-574.
6. Shastri Y.M., Bergis D., Povse N., et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008, 121:1099-1106.
7. Summerton C.B., Longlands M.G., Wiener K., Shreeve D.R. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002, 14:841-845.
8. Roseth A.G., Kristinsson J., Fagerhol M.K., et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?. Scand J Gastroenterol 1993, 28:1073-1076.
9. Maiden L., Thjodleifsson B., Theodors A., Gonzalez J., Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128:1172-1178.
10. D'Incà R., Dal Pont E., Di Leo V., et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007, 22:429-437.
11. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103:162-169.
12. Schoepfer A.M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008, 14:32-39.
13. Silberer H., Kuppers B., Mickisch O., et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005, 51:117-126.
14. Schroder O., Naumann M., Shastri Y., Povse N., Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007, 26:1035-1042.
15. Schoepfer A.M., Trummler M., Seeholzer P., Criblez D.H., Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007, 50:1697-1706.
16. Malickova K., Janatkova I., Bortlik M., Komarek V., Lukas M. Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests. Epidemiol Mikrobiol Imunol 2008, 57:147-153.
17. Manz M., Burri E., Rothen C., et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012, 12:5.
18. Van Assche G., Dignass A., Panes J., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
19. Stange E.F., Travis S.P., Vermeire S., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008, 2:1-23.
20. Allum W.H., Griffin S.M., Watson A., Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 2002, 50(Suppl. 5):v1-v23.
21. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:627-637.
22. Roseth A.G., Fagerhol M.K., Aadland E., Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992, 27:793-798.
23. Tibble J.A., Sigthorsson G., Foster R., Forgacs I., Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002, 123:450-460.
24. von Roon A.C., Karamountzos L., Purkayastha S., et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007, 102:803-813.
25. van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010, 341:c3369.
26. Kane S.V., Sandborn W.J., Rufo P.A., et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003, 98:1309-1314.
27. Sugi K., Saitoh O., Hirata I., Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996, 91:927-934.
28. Dai J., Liu W.Z., Zhao Y.P., Hu Y.B., Ge Z.Z. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007, 42:1440-1444.
29. Langhorst J., Boone J. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases. Drugs Today (Barc) 2012, 48:149-161.